How blood pressure predicts frailty transitions in older adults in a population-based cohort study: a multi-state transition model.


Journal

International journal of epidemiology
ISSN: 1464-3685
Titre abrégé: Int J Epidemiol
Pays: England
ID NLM: 7802871

Informations de publication

Date de publication:
10 08 2022
Historique:
received: 27 01 2021
pubmed: 16 10 2021
medline: 13 8 2022
entrez: 15 10 2021
Statut: ppublish

Résumé

Low blood pressure (BP) is associated with frailty in older adults. Our aim was to explore how BP predicts transitions between frailty states. We used data from the Lausanne cohort Lc65+, a population-based cohort of older adults randomly drawn from a population registry in Switzerland, in 2004, 2009 and 2014. BP was measured using a clinically validated oscillometric automated device and frailty was defined using Fried's phenotype, every 3 years. We used an illness-death discrete multi-state Markov model to estimate hazard ratios of forward and backward transitions between frailty states (outcome) in relation to BP categories (predictor of interest) with adjustment for sex, age and antihypertensive medication (other predictors). Among 4200 participants aged 65-70 years (58% female) at baseline, 70% were non-frail, 27% pre-frail and 2.0% frail. Over an average follow-up of 5.8 years, 2422 transitions were observed, with 1575 (65%) forward and 847 (35%) backward. Compared with systolic BP (SBP) <130 mmHg, the hazard ratio (95% confidence interval) of the transition from non-frail to pre-frail was 0.86 (0.74 to 1.00) for SBP 130-150 mmHg, and 0.89 (0.74 to 1.06) for SBP ≥150 mmHg. Compared with SBP <130 mmHg, the hazard ratio of the transition from pre-frail to frail was 0.71 (0.50 to 1.01) for SBP 130-150 mmHg, and 0.90 (0.62 to 1.32) for SBP ≥150 mmHg. Diastolic BP was a weaker predictor of forward transitions. BP categories had no strong relationship with either forward transitions or backward transitions in frailty states. If our findings are confirmed with greater precision and assuming a causal relationship, they would suggest that there is no well-defined optimal BP level to prevent frailty among older adults.

Sections du résumé

BACKGROUND
Low blood pressure (BP) is associated with frailty in older adults. Our aim was to explore how BP predicts transitions between frailty states.
METHODS
We used data from the Lausanne cohort Lc65+, a population-based cohort of older adults randomly drawn from a population registry in Switzerland, in 2004, 2009 and 2014. BP was measured using a clinically validated oscillometric automated device and frailty was defined using Fried's phenotype, every 3 years. We used an illness-death discrete multi-state Markov model to estimate hazard ratios of forward and backward transitions between frailty states (outcome) in relation to BP categories (predictor of interest) with adjustment for sex, age and antihypertensive medication (other predictors).
RESULTS
Among 4200 participants aged 65-70 years (58% female) at baseline, 70% were non-frail, 27% pre-frail and 2.0% frail. Over an average follow-up of 5.8 years, 2422 transitions were observed, with 1575 (65%) forward and 847 (35%) backward. Compared with systolic BP (SBP) <130 mmHg, the hazard ratio (95% confidence interval) of the transition from non-frail to pre-frail was 0.86 (0.74 to 1.00) for SBP 130-150 mmHg, and 0.89 (0.74 to 1.06) for SBP ≥150 mmHg. Compared with SBP <130 mmHg, the hazard ratio of the transition from pre-frail to frail was 0.71 (0.50 to 1.01) for SBP 130-150 mmHg, and 0.90 (0.62 to 1.32) for SBP ≥150 mmHg. Diastolic BP was a weaker predictor of forward transitions.
CONCLUSIONS
BP categories had no strong relationship with either forward transitions or backward transitions in frailty states. If our findings are confirmed with greater precision and assuming a causal relationship, they would suggest that there is no well-defined optimal BP level to prevent frailty among older adults.

Identifiants

pubmed: 34652417
pii: 6398053
doi: 10.1093/ije/dyab210
pmc: PMC9365628
doi:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1167-1177

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the International Epidemiological Association.

Références

J Am Geriatr Soc. 2012 Aug;60(8):1487-92
pubmed: 22881367
J Hum Hypertens. 2021 Mar;35(3):280-289
pubmed: 32346124
Int J Epidemiol. 2019 Dec 1;48(6):1752-1753j
pubmed: 31633757
Ann Intern Med. 2017 Mar 21;166(6):430-437
pubmed: 28135725
Hypertension. 2014 Mar;63(3):433-41
pubmed: 24324042
Arch Intern Med. 2007 Apr 9;167(7):635-41
pubmed: 17420420
J Am Med Dir Assoc. 2013 Nov;14(11):851.e1-6
pubmed: 24103860
Lancet. 2019 Oct 12;394(10206):1365-1375
pubmed: 31609228
JAMA Intern Med. 2018 Jan 1;178(1):93-99
pubmed: 29204655
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Arch Gerontol Geriatr. 2020 Jul - Aug;89:104102
pubmed: 32464423
BMC Geriatr. 2019 Apr 2;19(1):96
pubmed: 30940085
Biometrics. 1991 Jun;47(2):595-605
pubmed: 1912263
Circulation. 2018 Oct 23;138(17):e484-e594
pubmed: 30354654
Public Health Rev. 2018 Sep 3;39:26
pubmed: 30186660
Circulation. 2017 Jun 13;135(24):2357-2368
pubmed: 28432148
BMC Geriatr. 2008 Aug 18;8:20
pubmed: 18706113
Age Ageing. 2019 Dec 1;49(1):135-140
pubmed: 31665206
BMJ Open. 2018 Dec 28;8(12):e024406
pubmed: 30593554
Hypertension. 2016 May;67(5):820-5
pubmed: 26975708
J Clin Hypertens (Greenwich). 2019 Dec;21(12):1895-1904
pubmed: 31661601
J Gerontol A Biol Sci Med Sci. 2009 Jun;64(6):675-81
pubmed: 19276189
J Am Med Dir Assoc. 2010 Jun;11(5):356-64
pubmed: 20511103
JAMA. 2015 Jul 14;314(2):170-80
pubmed: 26172896
Lancet. 2019 Oct 12;394(10206):1376-1386
pubmed: 31609229

Auteurs

Daniela Anker (D)

Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland.
Graduate School for Health Sciences, University of Bern, Bern, Switzerland.

Cristian Carmeli (C)

Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland.

Marcel Zwahlen (M)

Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland.

Nicolas Rodondi (N)

Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Valérie Santschi (V)

La Source, School of Nursing Sciences, HES-SO University of Applied Sciences and Arts Western Switzerland, Delémont, Switzerland.

Yves Henchoz (Y)

Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.

Christina Wolfson (C)

Department of Epidemiology and Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montréal, Québec, Canada.

Arnaud Chiolero (A)

Population Health Laboratory (#PopHealthLab), University of Fribourg, Fribourg, Switzerland.
Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
Department of Epidemiology and Biostatistics and Occupational Health, School of Population and Global Health, McGill University, Montréal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH